Trial Profile
A Phase 1b, Open-label, Multi-center, Single Arm, Dose Finding Study to Assess Safety and Pharmacokinetics of the Oral Combination of Panobinostat and Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-polycythemia Vera-myelofibrosis (PPV-MF) or Post-essential Thrombocythemia-myelofibrosis (PET-MF)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary) ; Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 02 Jul 2020 Status changed from active, no longer recruiting to completed.
- 22 May 2020 Planned End Date changed from 29 May 2020 to 22 Jun 2020.
- 22 May 2020 Planned primary completion date changed from 29 May 2020 to 22 Jun 2020.